 |
2021 News Releases
Sept. 7, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Sept. 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read
Aug. 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Aug. 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results
Read
July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Read
July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
Read
July 2, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Read
June 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Read
June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Read
June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Read
May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
Read
May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results
Read
May 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Apr. 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read
Apr. 13, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Mar. 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Mar. 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference
Read
Mar. 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
Read
Feb. 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Read
Feb. 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
Feb. 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Read
Feb. 9, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Jan. 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
Read
Jan. 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Read
Jan. 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
Read
Jan. 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read
Jan. 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Read
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
